The Synergistic Effect of an ATP-Competitive Inhibitor of mTOR and Metformin on Pancreatic Tumor Growth

Ghada A Soliman; Surendra K Shukla; Asserewou Etekpo; Venugopal Gunda; Sharalyn M Steenson; Nagsen Gautam; Yazen Alnouti; Pankaj K Singh

doi:10.1093/cdn/nzaa131

The Synergistic Effect of an ATP-Competitive Inhibitor of mTOR and Metformin on Pancreatic Tumor Growth

Curr Dev Nutr. 2020 Aug 10;4(9):nzaa131. doi: 10.1093/cdn/nzaa131. eCollection 2020 Sep.

Authors

Ghada A Soliman¹, Surendra K Shukla², Asserewou Etekpo³, Venugopal Gunda², Sharalyn M Steenson⁴, Nagsen Gautam⁵, Yazen Alnouti⁵, Pankaj K Singh²

Affiliations

¹ Department of Environmental, Occupational, and Geospatial Health Sciences, CUNY Graduate School of Public Health and Health Policy, City University of New York, New York, NY, USA.
² The Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USA.
³ Nebraska Department of Health, Lincoln, NE, USA.
⁴ Department of Health Promotion, College of Public Health, University of Nebraska Medical Center, Omaha, NE, USA.
⁵ Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA.

Abstract

Background: The mechanistic target of rapamycin complex 1 (mTORC1) is a nutrient-sensing pathway and a key regulator of amino acid and glucose metabolism. Dysregulation of the mTOR pathways is implicated in the pathogenesis of metabolic syndrome, obesity, type 2 diabetes, and pancreatic cancer.

Objectives: We investigated the impact of inhibition of mTORC1/mTORC2 and synergism with metformin on pancreatic tumor growth and metabolomics.

Methods: Cell lines derived from pancreatic tumors of the KPC (Kras^G12D/+; p53^R172H/+; Pdx1-Cre) transgenic mice model were implanted into the pancreas of C57BL/6 albino mice (n = 10/group). Two weeks later, the mice were injected intraperitoneally with daily doses of 1) Torin 2 (mTORC1/mTORC2 inhibitor) at a high concentration (TH), 2) Torin 2 at a low concentration (TL), 3) metformin at a low concentration (ML), 4) a combination of Torin 2 and metformin at low concentrations (TLML), or 5) DMSO vehicle (control) for 12 d. Tissues and blood samples were collected for targeted xenometabolomics analysis, drug concentration, and cell signaling.

Results: Metabolomic analysis of the control and treated plasma samples showed differential metabolite profiles. Phenylalanine was significantly elevated in the TLML group compared with the control (+426%, P = 0.0004), whereas uracil was significantly lower (-38%, P = 0.009). The combination treatment reduced tumor growth in the orthotopic mouse model. TLML significantly decreased pancreatic tumor volume (498 ± 104 mm³; 37%; P < 0.0004) compared with control (1326 ± 134 mm³; 100%), ML (853 ± 67 mm³; 64%), TL (745 ± 167 mm³; 54%), and TH (665 ± 182 mm³; 50%) (ANOVA and post hoc tests). TLML significantly decreased tumor weights (0.66 ± 0.08 g; 52%) compared with the control (1.28 ± 0.19 g; 100%) (P < 0.002).

Conclusions: The combination of mTOR dual inhibition by Torin 2 and metformin is associated with an altered metabolomic profile and a significant reduction in pancreatic tumor burden compared with single-agent therapy, and it is better tolerated.

Keywords: KPC mouse model; antidiabetic drug; glycolysis; metabolomics; metformin; pancreatic cancer; phenylalanine; tricarboxylic acid cycle; xenometabolomics.

Abstract

Grants and funding